U.S. FDA panel recommends approval of Johnson & Johnson's depression drugAn advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression. The panel voted 14-2 in favor of the drug esketamine, developed to treat major depression in patients who have not benefited from at least two different therapies, saying its benefits outweighed the risks.




https://news.yahoo.com/u-fda-panel-r...--finance.html